Skip to main content
Caplight Logo









Forcefield Therapeutics

Forcefield Therapeutics

Private
LondonHealthcare & Life Scienceshttps://forcefieldtx.com/

Last Round

Series A

Jun 20, 2024

Total Funding Raised

$82.9M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Forcefield Therapeutics is a biotechnology company that develops therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

cardioprotective therapeuticsprotein therapeuticsmyocardial infarction treatmentheart attack therapyFunSelgene therapyAAV gene therapyadeno-associated virusAAVdrug discovery platformbiotech licensingvirtual R&Dcardiovascular medicineheart failure preventionpreclinical development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Forcefield Therapeutics Comparables

Compare Forcefield Therapeutics with similar companies based on industry and business-model similarity.

Forcefield Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Infensa Bioscience
84%
SERCA Pharmaceuticals
80%
Heqet Therapeutics
78%

Forcefield Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 20, 2024
Series AMar 28, 2024
SeedApr 25, 2022

Forcefield Therapeutics Investors

Notable investors and investment history

Forcefield Therapeutics investors
InvestorRounds
Roche Venture FundSeries A
SynconaSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors grew 68% MoM.

  • Jun 20, 2024

    $38.1M round led by Syncona.

Forcefield Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Forcefield Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Forcefield Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range8
Year Founded2022
Last FundingJun 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?